Sorafenib resistance and therapeutic strategies in hepatocellular carcinoma
文献类型：期刊论文
| 作者 | Zhang, Weijing1,3; Hong, Xuechuan2; Xiao, Yuling1,2,4; Wang, Hongbo3; Zeng, Xiaodong1 |
| 刊名 | BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
 |
| 出版日期 | 2025-07-01 |
| 卷号 | 1880期号:3页码:17 |
| 关键词 | Hepatocellular carcinoma Sorafenib Drug resistance Therapeutic strategy |
| ISSN号 | 0304-419X |
| DOI | 10.1016/j.bbcan.2025.189310 |
| 英文摘要 | Hepatocellular carcinoma (HCC) remains one of the most prevalent and lethal cancers globally. While surgical resection and liver transplantation offer potential cures for early-stage HCC, the majority of patients are diagnosed at advanced stages where such interventions are not viable. Sorafenib, a multi-target kinase inhibitor, has been a cornerstone in the treatment of advanced HCC since its approval in 2007. Despite its significant clinical impact, less than half of the treated patients derive long-term benefits due to the emergence of resistance and associated side effects. This review focuses on the role of sorafenib, an FDA-approved multi-target kinase inhibitor, in treating advanced HCC, discusses the mechanisms underlying its therapeutic effects and associated resistance, and explores additional therapeutic strategies being investigated to improve patient outcomes. |
| WOS关键词 | GROWTH-FACTOR RECEPTOR ; GEMCITABINE PLUS OXALIPLATIN ; PHASE-II TRIAL ; EPITHELIAL-MESENCHYMAL TRANSITION ; HEPARANASE INHIBITOR PI-88 ; REFAMETINIB BAY 86-9766 ; DRUG-RESISTANCE ; LENVATINIB RESISTANCE ; MULTIDRUG-RESISTANCE ; RAF/MEK/ERK PATHWAY |
| 资助项目 | Taishan Scholar Project[tsqn202211112] ; Taishan Scholar Project[tsqn202306320] ; National Natural Science Foundation of China[82273969] ; National Natural Science Foundation of China[82073888] ; National Natural Science Foundation of China[22477129] ; Shandong Provincial Natural Science Foundation[ZR2023MB085] ; Shandong Provincial Natural Science Foundation[ZR2024QH253] ; Shandong Laboratory Program[SYS202205] ; Special Supporting Funds for Leading Talents at or above the Provincial Level in Yantai |
| WOS研究方向 | Biochemistry & Molecular Biology ; Biophysics ; Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:001469697100001 |
| 出版者 | ELSEVIER |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/317479]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Wang, Hongbo; Zeng, Xiaodong |
| 作者单位 | 1.Bohai Rim Adv Res Inst Drug Discovery, Shandong Lab Yantai Drug Discovery, Yantai 264117, Peoples R China 2.Wuhan Univ, Zhongnan Hosp, Sch Pharmaceut Sci, Dept Cardiol, Wuhan 430071, Peoples R China 3.Yantai Univ, Collaborat Innovat Ctr Adv Drug Delivery Syst & Bi, Sch Pharm,Key Lab Mol Pharmacol & Drug Evaluat, Minist Educ, Yantai 264005, Peoples R China 4.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res & Ctr Pharmaceut, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhang, Weijing,Hong, Xuechuan,Xiao, Yuling,et al. Sorafenib resistance and therapeutic strategies in hepatocellular carcinoma[J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER,2025,1880(3):17. |
| APA | Zhang, Weijing,Hong, Xuechuan,Xiao, Yuling,Wang, Hongbo,&Zeng, Xiaodong.(2025).Sorafenib resistance and therapeutic strategies in hepatocellular carcinoma.BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER,1880(3),17. |
| MLA | Zhang, Weijing,et al."Sorafenib resistance and therapeutic strategies in hepatocellular carcinoma".BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER 1880.3(2025):17. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。